Loading clinical trials...

A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis | Clinical Trials | Clareo Health

COMPLETEDPHASE3

A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis

A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Subjects With Multiple Sclerosis Followed by an Open-Label Safety Extension

NCT01917019•Biogen

View on ClinicalTrials.gov

Summary

This is a multicenter study conducted in 3 parts. Part A is a double-blind placebo-controlled parallel-group period, and Part B and C are open-label extension periods. The primary objective of the double-blind study (Part A) is to assess the effect of Prolonged-Release Fampridine treatment on walking speed as measured by the T25FW (timed 25 foot walk) in Japanese participants with Multiple Sclerosis. The secondary objective of the double-blind portion of the study is to evaluate the safety and tolerability of prolonged-release Fampridine in this study population. The primary objective of the open-label extension study (Part B) is to evaluate the long-term safety profile of prolonged-release Fampridine. The primary objective of the additional open-label extension (Part C) is to provide participants who complete the study with continued access to prolonged-release fampridine until marketed drug can be used at the applicable site or until sponsor decision to discontinue the study.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Part A
•To be eligible to participate in Part A, candidates must meet the following eligibility criteria at screening or at the timepoint specified in the individual eligibility criterion listed (potential subjects who fail screening may be rescreened 1 time):
•1. Must have a diagnosis of primary-progressive, secondary progressive, progressive relapsing, or relapsing-remitting MS as defined by the revised McDonald Committee criteria (\[Lublin and Reingold 1996; McDonald 2001; Polman 2005\]) of at least 2 months duration.
•2. Must be able to complete the T25FW with or without a walking aid in 8 to 45 seconds at the screening visit.
•Part B
•To be eligible to participate in Part B, candidates must meet the following criteria at the Week 21 visit in Part A, which is the first visit for Part B:
•1\. Completed all visits in Part A of the study.
•Part C
•To be eligible to participate in Part C, candidates must meet the following criteria at the Week 52 visit in Part B, which is the first visit for Part C:
•1\. Completed all visits in Part B of the study.

Exclusion Criteria

•1. Known allergy to pyridine-containing substances, or any of the inactive ingredients of the prolonged-release fampridine tablet
•2. Any prior history of seizures, epilepsy, or other convulsive disorder, with the exception of febrile seizures in childhood, or prior history of epileptiform activity on electroencephalogram.
•3. Any form of renal impairment as defined by a creatinine clearance (CrCl) of \<80 mL/min (estimated by the central laboratory).
•4. Known history of cardiac arrhythmia or cardiac conduction disorders requiring medical or surgical intervention, or any clinically significant ECG abnormality (as determined by the Investigator) at the screening visit or Day 1.
•5. Any prior treatment with fampridine (4 AP) or 3,4 diaminopyridine in any formulation.
•6. Treatment with an investigational drug or approved therapy for investigational use within 30 days (or 5 half lives, whichever is longer) prior to the screening visit.
•7. Participation in an investigational study (with the exception of observational studies) within 30 days prior to the screening visit or plans to enroll in another interventional investigational study at any time during this study.

Locations (19)

Research Site

Bunkyō City, Japan

Research Site

Chiba, Japan

Research Site

Fuchū, Japan

Research Site

Fukuoka, Japan

Research Site

Kawagoe-shi, Japan

Research Site

Kodaira-shi, Japan

Research Site

Kyoto, Japan

Research Site

Morioka, Japan

Research Site

Niigata, Japan

Research Site

Obihiro, Japan

Key Dates

Start Date

August 1, 2013

Primary Completion Date

October 1, 2015

Completion Date

March 1, 2017

Last Updated

March 21, 2017

Enrollment

101

ACTUAL participants

Conditions

Multiple Sclerosis, Remittent ProgressiveMultiple Sclerosis, Primary ProgressiveRelapsing-Remitting Multiple SclerosisSecondary Progressive Multiple SclerosisMultiple Sclerosis

Interventions

Placebo

DRUG

BIIB041 (fampridine)

DRUG

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

NCT05359653

Multiple Sclerosis (MS)Multiple Sclerosis, Relapsing-Remitting+5 more

View study

RECRUITINGPHASE1

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

NCT06138132

Multiple SclerosisMultiple Sclerosis, Primary Progressive+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 21, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis

Inclusion Criteria

Exclusion Criteria

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.

Understanding the 'Durable Effect' Concept of B-cell Modulating Therapies

A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis

Cognition Evolution and MRI Markers in PPMS Patients on 2 Years